tbuckley/cabot-search huggingface dataset:
Incorporating Target Immunotherapy into Standard Conditioning Regimen Prior to Autologous Stem Cell Transplantaion (ASCT) Improves the Transplant Outcome for Pateints with Relapsed/Refractroy B Cell Non-Hodgkin Lymphoma (B-NHL).
Authors: Mohamed I. Farhat, Reem Karmali, Stephanie A. Gregory, Parameswaran Venugopal, Mohamad Kassar, Neel Shah, Terrance Brooks, Henry C. Fung
Journal: Blood (2007)
Lateral Flow Assay Based on Paper–Hydrogel Hybrid Material for Sensitive Point‐of‐Care Detection of Dengue Virus
Authors: Jane Ru Choi, Kar Wey Yong, Ruihua Tang, Yan Gong, Ting Wen, Hui Yang, Ang Li, Yook Chin Chia, Belinda Pingguan‐Murphy, Feng Xu
Journal: Advanced Healthcare Materials (2016)

Paper-based devices have been broadly used for the point-of-care detection of dengue viral nucleic acids due to their simplicity, cost-effectiveness, and readily observable colorimetric readout. However, their moderate sensitivity and functionality have limited their applications. Despite the above-mentioned advantages, paper substrates are lacking in their ability to control fluid flow, in contrast to the flow control enabled by polymer substrates (e.g., agarose) with readily tunable pore size and porosity. Herein, taking the benefits from both materials, the authors propose a strategy to create a hybrid substrate by incorporating agarose into the test strip to achieve flow control for optimal biomolecule interactions. As compared to the unmodified test strip, this strategy allows sensitive detection of targets with an approximately tenfold signal improvement. Additionally, the authors showcase the potential of functionality improvement by creating multiple test zones for semi-quantification of targets, suggesting that the number of visible test zones is directly proportional to the target concentration. The authors further demonstrate the potential of their proposed strategy for clinical assessment by applying it to their prototype sample-to-result test strip to sensitively and semi-quantitatively detect dengue viral RNA from the clinical blood samples. This proposed strategy holds significant promise for detecting various targets for diverse future applications.
Aberrantly Expressed Neutrophil Elastase (ELA2) Cleaves Cyclin E (CCNE) in the Nucleus and Cytoplasm of Acute Lymphocytic Leukemia Yielding Novel Leukemia-Associated Antigens.
Authors: Ken Ishiyama, Yukio Kondo, Eric D. Wieder, Sijie Lu, Jeffrey J. Molldrem
Journal: Blood (2006)
Identification of Novel Activities of Immunomodulatory Drugs: Cytoskeleton Reorganization through Modulation of Rho GTPases
Authors: Yibing Xu, JianWu Li, Greg Ferguson, Frank Mercurio, Gody Khambatta, Lisa Morrison, Antonia Lopez-Girona, Laura G Corral, David Webb, Brydon L. Bennett, Weilin Xie
Journal: Blood (2008)
PARE0006 Identification and Prioritization of Resources for Rheumatic Patients (Reumappa)
Authors: M. Gobbo, L. Carmona
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Spanish Rheumatology League (Liga Reumatolόgica Española, LIRE) is developing an application for mobile devices and web browsers that incorporates a map of resources for rheumatic patients and professionals who treat them (Reumappa). This app helps locate with ease professionals and specialized services in rheumatic pathologies in Spain. <h3>Objectives</h3> Identify and prioritize resources to be included in Reumappa. <h3>Methods</h3> Focus group with characteristic rheumatic diseases patients (Rheumatoid arthritis, Osteoporosis, Sjögren, Scleroderma, Spondylarthritis, Psoriatic Arthritis, Fibromyalgia, Behcet9s disease, Lupus, and Osteoarthritis), sex (4 male, 6 female), age (3&lt;45, 5 between 45 and 65, 2&gt;65) and years of disease progression (4&lt;10, 6&gt;10). Key question for identification: “<i>If you could use an app to obtain information about professionals, services or useful things to cope better with your condition what would you expect to find in it?</i>” Prioritization was established by scoring from 0 = no relevance to 10 = maximum relevance. <h3>Results</h3> Resources that patients identified as important to help them with their disease and their appraisals according to their relevance (mean, SD) are in table 1. <h3>Conclusions</h3> There are a number of resources that can be helpful for rheumatic patients. Among professional resources most popular medical specialists are rheumatologists, ophthalmologists, pediatricians, gastroenterologists and dermatologists; nonmedical professionals that are considered most necessary are physiotherapists and psychologists. Services identified as most important are patient associations, units specialized in specific pathologies, orthopedics stores and gyms. <h3>Disclosure of Interest</h3> None declared
Notice of Duplicate Publication: Heated, Humidified High-Flow Nasal Cannula vs Nasal Continuous Positive Airway Pressure for Respiratory Distress Syndrome of Prematurity: A Randomized Clinical Noninferiority Trial (<i>JAMA Pediatr</i>. doi: 10.1001/jamapediatrics.2016.1243 )
Authors: Anna Lavizzari, Mariarosa Colnaghi, Francesca Ciuffini, Chiara Veneroni, Ivan Cortinovis, Stefano Musumeci, Fabio Mosca
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
B-Cell Prolymphocytic Leukemia (B-PLL) and Chronic Lymphocytic Leukemia (CLL) Express Distinct Genomic Profiles.
Authors: Ilaria Del Giudice, Nnenna Osuji, Tim Dexter, Estella Matutes, Vasantha Brito-Babapulle, Nilima Parry-Jones, Daniel Catovsky
Journal: Blood (2005)
A New Formulation of Recombinant Human Factor IX Is Bioequivalent to BeneFIX: A Double-Blind, Randomized, Crossover Pharmacokinetic and Open-Label Safety and Efficacy Study.
Authors: Jerry Sherman Powell, Thierry Lambert, F. Hernández Navarro, Michael Recht, Sharon T. Sullivan, Chandrasekhar Udata, Leslie C. Lilly, David A. Roth
Journal: Blood (2005)
IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F
Authors: Nanna Sulai, Thitina Jimma, Terra L Lasho, Christy Finke, Ryan A Knudson, Rebecca F McClure, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2011)
SAT0261 Different Treatment Strategies for Chronic Non-Bacterial Osteomyelitis: The Experince of 52 Patients
Authors: M.M. Kostik, O. Kopchak, I. Chikova, V. Masalova, M. Dubko, L. Snegireva, E. Isupova, O. Kalashnikova, A. Mushkin, V. Chasnyk
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Chronic non-bacterial osteomyelitis (CNO) is a heterogenous group of immune-mediated inflammatory bone diseases, often co-exist with other rheumatic diseases. There are no approved treatments for CNO except non-steroid anti-inflammatory drugs (NSAID). The efficacies of methotrexate (MTX), sulfasalazine, pamidronate (PAM), anti-IL1 and TNFα-inhibitors (TNFα-inh) were shown in different reports. <h3>Objectives</h3> The aim of study: to compare the efficacy of non-randomized different treatment approaches in pediatric patient CNO cohort. <h3>Methods</h3> 52 children (25 M and 27 F) with CNO has average age at the onset of disease 8.4 years (5.4÷11.0), the number of foci - 3.0 (2.0÷6.0, incl. multifocal cases in 80.8%), fever at the onset – 38.5%, spine involvement - 34.6%, positive family autoimmune diseases (AID) history - 7.7%, concomitant AID - 67.3%. NSAID was the first-line treatment for non-vertebral cases, as well as PAM for vertebral involvement. Second-line treatment includes MTX, PAM and TNFα-inh. Dynamics of pain, patient9s (PVAS) and physician9s (MDVAS) assessment and ability to each medication to achieve remission of CNO activity we evaluated. <h3>Results</h3> According to the NSAID, MTX, SSZ, PAM and TNFα-inh groups next data were registered: PVAS: -14.2% (p=0.05), -50.0% (p=0.04), -23.1 (p=0.89), -83.3% (p=0.0001), -73.6% (p=0.0007); pain: -21.9% (p=0.01), -18.6% (p=0.13), +36,4 (p=0.89), -79.7% (p=0.00016), -74.1%, (p=0.0015); MDVAS: -13.8% (p=0.13); -56.4% (p=0.09), +30.8% (p=0.89), -74.7%, (p=0.0001), -82.1 (p=0.0015) respectively. The ability of each treatment strategy to achieve the CNO remission was 52.6%, 44.4%, 57,1%, 88.8% and 73.3% respectively (log-rank test, p=0,001, figure). TNFα-inh usually used as second-third line treatment in cases where other options, especially PAM were fall. <h3>Conclusions</h3> The most effective treatment approaches for CNO were PAM and TNFα-inh. The randomized controlled trials for assessment efficacy and safety of these medications is mandatory to confirm these results. <h3>Disclosure of Interest</h3> None declared
Short Cycle of Immunochemotherapy Followed by Radiation Therapy Compared with Prolonged Cycles of Immunochemotherapy for Localized DLBCL: The Osaka Lymphoma Study Group (OLSG) Retrospective Analysis
Authors: Yoshiki Terada, Hironori Take, Hirohiko Shibayama, Koji Hashimoto, Maki Kuwayama, Norie Fujii, Yasuhiko Azenishi, Yasuhiro Maeda, Tamotu Yamagami, Nobuhiko Uoshima, Machiko Tsukaguchi, Osamu Semba, Hideki Mitui, Shuji Ueda, Toshihiro Soma, Masashi Nakagawa, Mituhiro Matuda, Fumiaki Urase, Teruo Kiyoi, Hitoshi Yoshida, Hiroyuki Sugahara, Kenichi Yamashita, Nobuhiko Tominaga, Takeshi Kubota, Nobuyoshi Arima, Shinichirou Mori, Toshiharu Tamaki, Takahiro Okamoto, Naoyuki Anzai, Hiroshi Akasaka, Rie Tabata, Junichiro Ikeda, Naoki Wada, Katsuyuki Aozasa, Masayuki Hino
Journal: Blood (2012)
CD28-Directed T Cell Costimulation Blockade with Abatacept to Prevent GvHD During High-Risk Unrelated HSCT: A First-in-Disease Feasibility Trial,
Authors: Leslie S. Kean, Amelia Langston, Muna Qayad, H. Jean Khoury, Divya Tiwari, Cynthia Couture, Heather Renfroe, Sharon Sen, Jennifer Robertson, Edmund K Waller, John T. Horan
Journal: Blood (2011)
Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study
Authors: James R. Berenson, Ori Yellin, Alberto Bessudo, Ralph V. Boccia, Stephen J. Noga, Donald S. Gravenor, Dipti Patel-Donnelly, Robert S. Siegel, Tarun Kewalramani, Edward J. Gorak, Regina A. Swift, Debra Mayo
Journal: Blood (2011)
MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,
Authors: Massimo Breccia, Vincenzo Federico, Giuseppina Loglisci, Roberto Latagliata, Michelina Santopietro, Adriano Salaroli, Alessandra Serrao, Gioia Colafigli, Agostino Tafuri, Giuliana Alimena
Journal: Blood (2011)
Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases
Authors: Debbie M. Ferns, A. Marijne Heeren, Sanne Samuels, Maaike C. G. Bleeker, Tanja D. de Gruijl, Gemma G. Kenter, Ekaterina S. Jordanova
Journal: Journal for ImmunoTherapy of Cancer (2016)

<h3>Background</h3> Tumors avoid destruction by cytotoxic T cells (CTL) and natural killer (NK) cells by downregulation of classical human leukocyte antigens (HLA) and overexpression of non-classical HLA. This is the first study to investigate HLA expression in relation to histology (squamous cell carcinoma (SCC) vs. adenocarcinoma (AC)), clinicopathological parameters and survival in a large cervical cancer patient cohort. <h3>Methods</h3> Classical (HLA-A and HLA-B/C)- and non-classical HLA molecules (HLA-E and HLA-G) were studied on primary tumors and paired lymph node (LN) metastases from cervical cancer patients (<i>n</i> = 136) by immunohistochemistry. The Chi<sup>2</sup> test was used for the comparison of clinicopathological characteristics between SCC and AC patients. The Related-Samples Wilcoxon Signed Rank test was used to compare HLA expression between the primary tumor and metastasis in LN. Patient survival rates were analyzed by Kaplan-Meier curves and Log Rank test. The Mann-Whitney <i>U</i> Test was used to compare the distribution of HLA class I expression between SCC and AC. <h3>Results</h3> Decreased expression of HLA-A (SCC <i>P</i> &lt; 0.001), HLA-B/C (SCC <i>P</i> &lt; 0.01; AC <i>P</i> &lt; 0.01) and total classical HLA (SCC <i>P</i> &lt; 0.001; AC <i>P</i> = 0.02) was apparent in metastatic tumor cells compared to the primary tumor. In primary SCC, there was a clear trend towards complete loss of HLA-A (<i>P</i> = 0.05). SCC metastases showed more complete loss of HLA-A, while AC metastases showed more complete loss of HLA-B/C (<i>P</i> = 0.04). In addition, tumor size and parametrium involvement were also related to aberrant HLA class I expression. No significant associations between HLA expression and disease-specific (DSS) or disease-free survival (DFS) were found in this advanced disease cohort. However, in the SCC group, samples showing loss of HLA-A or loss of total classical HLA but positive for HLA-G were linked to poor patient survival (DSS <i>P</i> = 0.001 and <i>P</i> = 0.01; DFS <i>P</i> = 0.003 and <i>P</i> = 0.01, for HLA-A and total classical HLA, respectively). <h3>Conclusion</h3> These results strengthen the idea of tumor immune escape variants leading to metastasis. Moreover, SCC tumors showing downregulation of HLA-A or total classical HLA in combination with HLA-G expression had poor prognosis. Our findings warrant further analysis of HLA expression as a biomarker for patient selection for CTL- and NK- cell based immunotherapeutic intervention.
Anatomical Distributions of Basal Cell Carcinoma and Squamous Cell Carcinoma in a Population-Based Study in Queensland, Australia
Authors: Padmini Subramaniam, Catherine M. Olsen, Bridie S. Thompson, David C. Whiteman, Rachel E. Neale
Journal: JAMA Dermatology (2016)

Keratinocyte cancers (KCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are the most common cancers among fair-skinned populations worldwide. Although studies have indicated that the anatomical distribution of BCC and SCC differ, few have compared them directly in well-defined population samples.To describe and compare the anatomical distribution of BCC and SCC in a population-based sample in Queensland, Australia.This study was nested within the population-based QSkin Sun and Health Study in Queensland, Australia. Of 37 103 study participants linked to national medical insurance records, 3398 diagnosed with KCs from September 1, 2010, to September 30, 2012, were identified, and information about their KCs was extracted from pathology reports. Data were analyzed from January 1, 2013, to March 30, 2016.The relative tumor densities (RTDs) on defined body sites, calculated by dividing the proportion of tumors occurring at a specified site by the proportion of skin area of that site.A total of 5150 KCs with complete data were identified in 2374 study participants (1339 men [56.4%] and 1035 women [43.6%]; mean [SD] age, 59.7 [7.4] years). Of these, 3846 KCs (74.7%) were BCCs. Most BCCs were on the head and/or neck (1547 [40.2%]) and the trunk (1305 [33.9%]); most SCCs were on the head and/or neck (435 [33.4%]) and upper limbs (455 [34.9%]). The greatest differences in RTDs between BCC and SCC were on the hand (BCC:SCC ratio, 1:14) and the back and/or buttocks (BCC:SCC ratio, 8:1). Relative tumor densities of KCs were higher on the scalp and ear in men compared with women, and on the upper arm in women compared with men. The pattern of RTDs did not differ with age for BCC. Compared with younger adults (40-54 years), the RTDs in older adults (55-69 years) were 2-fold higher for SCC on the scalp (0.38 [95% CI, 0.00-0.81] vs 1.07 [95% CI, 0.75-1.38]) and the back and/or buttocks (0.05 [95% CI, 0.00-0.12] vs 0.12 [95% CI, 0.07-0.16]).The high RTDs on sun-exposed body sites for BCC and SCC are in keeping with sun exposure as the primary etiologic factor for both tumors. However, for BCC, the low RTD on the hand and high RTDs on less sun-exposed sites suggest a complex association between sun exposure and occurrence of BCC. Knowledge about the anatomical distribution of BCC and SCC may provide insight into their diagnoses and causes.
THU0239 Performance of Disease Activity Measures in Juvenile Spondyloarthritis in A Placebo Controlled Trial with Infliximab
Authors: S. Ramiro, J.C. Casasola-Vargas, D. van der Heijde, R. Landewé, R. Burgos-Vargas
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Several outcome measures in trials with juvenile-onset spondyloarthritis (Jo-SpA) have been borrowed from trials in juvenile idiopathic arthritis and from adult spondyloarthritis, but a proper psychometric analysis has never been conducted in patients with Jo-SpA. <h3>Objectives</h3> To assess discriminatory aspects of several disease activity outcome measures and response criteria for Jo-SpA. <h3>Methods</h3> Data from a previously reported 12-week RCT comparing infliximab (IFX) and placebo (PBO) in patients &lt;18 years with Jo-SpA and onset &lt;16 years of age were analyzed. The primary endpoint of the trial was the number of active joints (both swollen and tender). Several other disease activity measures and response criteria were also tested (Table). Statistics to determine how well disease activity measures could discriminate between IFX and PBO included “standardized mean difference” (SMD) and “Guyatt9s effect size”. Both statistics are standardized measures to compare change from baseline per group. For categorical response criteria, the chi-square test (χ<sup>2</sup>) was used. Higher numbers indicate better discriminatory capacity. <h3>Results</h3> Patients were randomised to IFX (n=12) and PBO (n=14). Of the continuous measures, the ASDAS showed the best and very good discrimination between IFX and PBO (SMD:1.98; Guyatt: 4.28) (Table). The physician9s global, CRP, JADAS and JSpADA also discriminated well. The BASDAI (or its separate items), BASFI and spinal mobility measures performed worse. Of the response criteria ASAS40 and ACR Pedi 90 discriminated best between IFX and PBO (Table). ASDAS response criteria and ACR Pedi 30–70 also performed well. <h3>Conclusions</h3> Of all continuous measures tested in adult axial SpA the ASDAS discriminates best between active treatment and PBO in patients with Jo-SpA. But the child specific JSpADA also performs well. Of all response criteria tested the child-specific ACR Pedi 30 to 90, as well as the adult ASAS40 and ASDAS response criteria work well. One of these measures should be used as primary endpoint in trials with Jo-SpA. <h3>Acknowledgement</h3> Schering-Plough Mexico funded this trial as an investigator-initiated study <h3>Disclosure of Interest</h3> None declared
Increased M2 Macrophages and Higher Levels Of The Tribble Family Member Trib1 In Monocytes Are Associated With Progressive Disease In Multiple Myeloma (MM) Patients
Authors: Haiming Chen, Mingjie Li, Suzie Vardanyan, Jillian Gottlieb, Cathy Wang, Kevin Delijani, Joseph Ben-Zvi, Mitchell Song, Ran Halleluyan, Eric Sanchez, Benjamin Bonavida, James R. Berenson
Journal: Blood (2013)
Sustained Engraftment Using Fludarabine, Melphalan and Thiotepa Conditioning for Haploidentical Stem Cell Transplantation.
Authors: Stefan O. Ciurea, Suhail Qureshi, Gabriela Rondon, Susana Pesoa, Pedro Cano, John McMannis, Sergio Giralt, Marcos de Lima, Marcelo Fernandez-Vina, Richard E. Champlin, James Gajewski
Journal: Blood (2007)
Cutaneous Nodules and Erythematous Plaques on the Extremities
Authors: Cristian Scatena, Vieri Grandi, Giovanni Beltrami
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Anabolic Androgen (Oxymetholone) Improved Failure Free Survival in Childhood Severe Aplastic Anemia Responding to Immunosuppressive Therapy.
Authors: Dae-Chul Jeong, Hui Sung Hwang, Bin Cho, Nak Gyun Chung, Pil Sang Chang, Dae Hyung Lee, Young Joo Kwon, Sun Young Kim, Young Shil Park, Ji Kyoung Park, Hack Ki Kim
Journal: Blood (2006)
Prospecitve Quantitative PCR Monitoring of Allogeneic Stem Cell Transplant (SCT) Patients at High Risk for EBV Associated PTLD.
Authors: Hamdy Omar, Hans Hägglund, Åsa Gustafsson-Jernberg, Katarina Le Blanc, Jonas Mattsson, Mats Remberger, Olle Ringdén, Elda Sparrelid, Mikael Sundin, Jacek H. Winiarski, Zhibing Yun, Per T. Ljungman
Journal: Blood (2007)